StreetInsider.com News Articles

Form SCHEDULE 13G LB PHARMACEUTICALS INC Filed by: JPMORGAN CHASE & CO

Thu, 16 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260716/26779573.html

Form SCHEDULE 13G LB PHARMACEUTICALS INC Filed by: JPMORGAN CHASE & CO

Thu, 16 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260716/26779573.html

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:38:00 -0400

NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), today announced that it has granted to Christopher Zergebel, the new Senior Vice President, Clinical Operations of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on July 10, 2026, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Mr. Zergebel entering into employment with LB Pharmaceuticals.

Mr. Zergebel received an option

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:38:00 -0400

Mr. Zergebel received an option

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:38:00 -0400

Mr. Zergebel received an option

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:38:00 -0400

Mr. Zergebel received an option

Wolfe Research Starts LB Pharmaceuticals Inc (LBRX) at Outperform

Tue, 07 Jul 2026 05:32:33 -0400

Wolfe Research analyst Rudy Li initiates coverage on LB Pharmaceuticals Inc (NASDAQ: LBRX) with a Outperform rating and a price target of $45.00.

The analyst comments "The company is developing LB-102 as a next-gen product improving upon amisulpride, which was an antipsychotic product approved OUS but not in the US. The molecular modification of methylation leads to better brain penetration, potentially enabling lower doses and better safety. LB-102 has established clear POC in a Ph2 schizophrenia study, demonstrating strong efficacy and a favorable safety profile. We believe that LB-102 is a real product that could get approval in schizophrenia, and that

Wolfe Research Starts LB Pharmaceuticals Inc (LBRX) at Outperform

Tue, 07 Jul 2026 05:32:33 -0400

Wolfe Research analyst Rudy Li initiates coverage on LB Pharmaceuticals Inc (NASDAQ: LBRX) with a Outperform rating and a price target of $45.00.

LB Pharmaceuticals names Christopher Zergebel as SVP of clinical ops

Tue, 30 Jun 2026 08:02:07 -0400

LB Pharmaceuticals Inc. (Nasdaq: LBRX) has appointed Christopher Zergebel as Senior Vice President of Clinical Operations, according to a press release from the biopharmaceutical company.

Zergebel brings more than 25 years of global development operations experience. He previously served as Vice President of Development Operations at Cellectis Biologics, where he led global clinical development strategy and operations from early-stage through post-approval trials. He holds a B.A. in Biology from Boston University.

The appointment comes as LB Pharmaceuticals advances multiple clinical programs for its lead candidate, LB-102. The company currently has a Phase 3 trial in schizophrenia and a Phase 2 trial in

LB Pharmaceuticals names Christopher Zergebel as SVP of clinical ops

Tue, 30 Jun 2026 08:02:07 -0400

LB Pharmaceuticals Inc. (Nasdaq: LBRX) has appointed Christopher Zergebel as Senior Vice President of Clinical Operations, according to a press release from the biopharmaceutical company.

The appointment comes as LB Pharmaceuticals advances multiple clinical programs for its lead candidate, LB-102. The company currently has a Phase 3 trial in schizophrenia and a Phase 2 trial in

LB Pharmaceuticals names Christopher Zergebel as SVP of clinical ops

Tue, 30 Jun 2026 08:02:07 -0400

LB Pharmaceuticals Inc. (Nasdaq: LBRX) has appointed Christopher Zergebel as Senior Vice President of Clinical Operations, according to a press release from the biopharmaceutical company.

The appointment comes as LB Pharmaceuticals advances multiple clinical programs for its lead candidate, LB-102. The company currently has a Phase 3 trial in schizophrenia and a Phase 2 trial in

LB Pharmaceuticals names Christopher Zergebel as SVP of clinical ops

Tue, 30 Jun 2026 08:02:07 -0400

LB Pharmaceuticals Inc. (Nasdaq: LBRX) has appointed Christopher Zergebel as Senior Vice President of Clinical Operations, according to a press release from the biopharmaceutical company.

The appointment comes as LB Pharmaceuticals advances multiple clinical programs for its lead candidate, LB-102. The company currently has a Phase 3 trial in schizophrenia and a Phase 2 trial in

LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations

Tue, 30 Jun 2026 08:00:00 -0400

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations.

Mr. Zergebel, a seasoned biotechnology executive with more than 25 years of global development operations experience, brings deep expertise in growing and leading cross-functional teams including clinical operations, data management, and project and portfolio management.